Marsberg, Germany; 27th September 2024 – H&T Presspart (a division of the Heitkamp & Thumann Group), a world market leader in the development and manufacturing of inhalation drug delivery systems, is pleased to announce another major investment in pressurized metered-dose inhaler (pMDI) dose counter manufacturing capacity at the site in Marsberg, Germany.

Due to strong demand growth, H&T Presspart will be making another multi-million Euro investment in cleanroom infrastructure, injection moulding, tooling and assembly.

The addition of a new dose counter production line aligns with H&T Presspart’s strategy to provide high-quality drug delivery devices that meet stringent regulatory and patient needs. Christian Kraetzig, President H&T Presspart, commented ‘This strategic investment underlines our continued commitment to serving our customers’ needs as they grow in the pMDI market and ensuring to make pMDIs with dose counters available to patients worldwide.’